Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
cirrhosis save search
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
ETNB | $9.31 2.53% 2.47% 580K
|
Health Technology
|
| O: 0.45%
H: 3.29%
C: 0.53%
metabolic cirrhosis treatment fibrosis prime ema
Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: -0.15%
H: 8.76%
C: 8.09%
cirrhosis pruritus granted treatment designation therapy
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
BHC | $8.45 -2.76% 0.0% 2.4M
|
Health Technology
|
| O: 1.18%
H: 1.81%
C: 0.52%
liver disease report health pharmaceuticals trends
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Published: 2023-10-09 (Crawled : 20:00) - globenewswire.com
AKRO | $20.79 0.15% 0.14% 710K
|
Health Technology
|
| O: -59.06%
H: 0.0%
C: -8.66%
cirrhosis efruxifermin therapeutics results nash study
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: -2.08%
H: 3.72%
C: 3.19%
cirrhosis liver positive meeting hypertension therapeutics study
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: 0.0%
H: 3.24%
C: -1.63%
cirrhosis liver update program therapeutics
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
Published: 2023-09-21 (Crawled : 12:30) - globenewswire.com
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: -6.92%
H: 2.24%
C: 1.39%
cirrhosis study
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
Published: 2023-09-07 (Crawled : 17:00) - globenewswire.com
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: 2.44%
H: 4.76%
C: 4.76%
cirrhosis liver therapeutics nash
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
Published: 2023-07-27 (Crawled : 11:00) - biospace.com/
LPCN | $5.07 -3.8% -2.13% 21K
|
Health Technology
|
| O: 25.35%
H: 8.53%
C: -5.38%
cirrhosis study phase 2
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
Published: 2023-07-18 (Crawled : 12:20) - globenewswire.com
GRFS | $6.3 0.32% 0.32% 740K
|
Health Technology
|
| O: 0.1%
H: 7.43%
C: 4.58%
albutein cirrhosis therapy study
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL | $213.49 0.68% 0.85% 680K
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $5.07 -3.8% -2.13% 21K
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | $145.79 0.96% 0.94% 400K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $20.79 0.15% 0.14% 710K
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: 1.58%
H: 1.03%
C: 0.0%
cirrhosis liver positive meeting therapeutics study
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
CANF | $1.98 0.0% 8.7K
|
Health Technology
|
| O: 10.08%
H: 0.0%
C: -7.69%
namodenoson cirrhosis liver
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: 0.0%
H: 10.24%
C: 8.29%
cirrhosis liver therapeutics study
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
Published: 2023-01-04 (Crawled : 21:00) - inventivapharma.com
IVA | $3.3 -0.9% -0.3% 14K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -7.84%
cirrhosis trial nash
Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis
Published: 2022-12-19 (Crawled : 13:20) - prnewswire.com
LPCN | $5.07 -3.8% -2.13% 21K
|
Health Technology
|
| O: 7.65%
H: 1.64%
C: -1.88%
cirrhosis study phase 2
Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: -1.85%
H: 6.28%
C: 2.52%
cirrhosis liver meeting therapeutics positive study phase 2b
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
Published: 2022-09-30 (Crawled : 12:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -9.2%
H: 0.47%
C: -6.38%
pharmaceuticals cirrhosis nash study
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
Published: 2022-08-31 (Crawled : 14:00) - biospace.com/
HTGC F | $18.69 1.25% 0.59% 780K
|
Finance
|
| O: 0.43%
H: 0.21%
C: -0.42%
MDGL | $213.49 0.68% 0.85% 680K
|
Health Technology
|
| O: 1.4%
H: 9.87%
C: 7.87%
treatment cirrhosis nash study
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022
Published: 2022-06-21 (Crawled : 12:20) - globenewswire.com
GALT | $3.06 -9.2% -10.31% 310K
|
Health Technology
|
| O: -4.65%
H: 0.0%
C: 0.0%
cirrhosis liver therapeutics international
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.